Sangamo Biosciences (SGMO) Tops Q3 EPS by 4c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Lumentum shares fall after hitting 52-week high
- Stryker invests $400M in CMR Surgical with option to acquire
Sangamo Therapeutics Reports Third Quarter 2017 Financial Results
November 9, 2017 4:01 PM ESTRICHMOND, Calif., Nov. 9, 2017 /PRNewswire/ --Â Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its third quarter 2017 financial results and recent accomplishments.
"We continue to make progress on the key priorities we laid out at the beginning of 2017," said Dr. Sandy... More



